Guildford, United Kingdom

James Fidge

This inventor holds 3 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Incyte Corporation. Active years: 2024-2026.

USPTO Granted Patents = 3 

% Patents Active = 66.7

 

Average Co-Inventor Count = 5.3

ph-index = 1


Company Filing History:


Years Active: 2024-2026

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: James Fidge: Innovator in Dermatological Treatments

Introduction

James Fidge is a notable inventor based in Guildford, GB. He has made significant contributions to the field of dermatology through his innovative research and development of treatments for various skin diseases. His work is particularly focused on the use of JAK inhibitors in combination with vitamin D analogs.

Latest Patents

James Fidge holds a patent for a JAK inhibitor with a vitamin D analog for the treatment of skin diseases. This patent addresses the topical treatment of conditions such as psoriasis, atopic dermatitis, alopecia, vitiligo, and several other skin disorders. The invention utilizes a JAK inhibitor or its pharmaceutically acceptable salt, along with vitamin D3 or its analog, to provide effective treatment options for patients suffering from these conditions.

Career Highlights

Fidge is currently associated with Incyte Corporation, where he continues to advance his research in dermatological therapies. His dedication to improving patient outcomes through innovative treatments has established him as a respected figure in the field.

Collaborations

James Fidge has collaborated with notable colleagues, including Paul Smith and Zheng Zhang. These partnerships have contributed to the development and refinement of his innovative approaches to skin disease treatments.

Conclusion

James Fidge's work exemplifies the impact of innovation in the medical field, particularly in dermatology. His contributions through patents and collaborations continue to pave the way for new treatment options for patients with skin diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…